Semaglutide Slows Biological Aging in HIV

A new study published in Tata Communications, led by Michael Francis Crotty of the University of California, San Diego, provides the first randomized, placebo-controlled clinical evidence that Semaglutide, a widely used GLP-1 drug, slows down the accumulation of biological aging markers in the DNA of adults with HIV. The study analyzed data from 108 adults with HIV-associated lipohypertrophy, finding that participants treated with Semaglutide exhibited a broad pattern of slower biological aging across various epigenetic clocks, including a 9% slowing in the pace of aging as measured by the DunedinPACE epigenetic clock. A related pilot study published in List of Nature Research journals also supported these findings, showing Semaglutide reduced the rate of biological aging in participants with HIV and metabolic dysfunction-associated steatotic liver disease. Researchers caution that the drug does not reverse aging but influences pathways involved in age-related diseases. The United States — National Institutes of Health and the James B. Pendleton Charitable Trust funded these studies.